People taking higher doses of tirzepatide are more likely to stop using it because of side effects, even though it works better at those doses.

50

Pro

0

Against

Evidence from Studies

Supporting (1)

50

Community contributions welcome

50

Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis

Systematic Review With Meta-Analysis

Human

2025

The study found that more people stopped taking tirzepatide because of side effects, especially at higher doses, which matches what the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis

Score: 50

DOI: 10.3389/fendo.2025.1593134

Similar Assertions

Tirzepatide doesn’t cause more serious health problems than a placebo in adults, even though it can cause mild stomach issues — overall, it seems safe to use for several months.

50

0

81%

People taking tirzepatide are more likely to get stomach issues like nausea, vomiting, or constipation than those on a sugar pill, especially at higher doses — but most of these side effects aren’t severe.

50

0

74%

People with obesity or type 2 diabetes who took a drug called tirzepatide lost a lot of weight—more when they took higher doses—and the effect lasted up to about three years.

50

0

73%

People with obesity or type 2 diabetes who take tirzepatide are much more likely to lose a meaningful amount of weight—like 5%, 10%, or even 15% of their body weight—compared to those who don’t, and the more they take, the better the results seem to be.

50

0

72%